2013’s Top Biopharma Dealmakers
Biopharma firms exchanged licenses for cancer assets more than any other therapeutic area in 2013; also in the cancer field, Amgen completed the largest acquisition, buying Onyx for $9.2 billion. J&J was the leader in alliances, penning 20 deals.
You may also be interested in...
Big launches, clinical success in key therapeutic areas like cancer immunotherapy, and renewed interest in biotech from a broad investor base floated the biopharma world through 2013’s average year for FDA approvals, the rocky rollout of the Affordable Care Act, and increasing concern about drug prices.
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.